Ticker > Company >

Guj. Themis Biosyn share price

Gujarat Themis Biosyn Ltd.

NSE: GUJTHEM BSE: 506879 SECTOR: Pharmaceuticals & Drugs  76.45 K   745   83

380.00
+1.25 (0.33%)
NSE: Today, 12:34 PM

Price Summary

Today's High

₹ 389

Today's Low

₹ 379.4

52 Week High

₹ 410.7

52 Week Low

₹ 208

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

4140.68 Cr.

Enterprise Value

4158.02 Cr.

No. of Shares

10.9 Cr.

P/E

92.84

P/B

16.08

Face Value

₹ 1

Div. Yield

0.18 %

Book Value (TTM)

₹  23.63

CASH

12.55 Cr.

DEBT

29.89 Cr.

Promoter Holding

70.86 %

EPS (TTM)

₹  4.09

Sales Growth

-11.2%

ROE

21.69 %

ROCE

27.48%

Profit Growth

-17.56 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Gujarat Themis Biosyn Ltd.

Rifamycin-S Lovastatin

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-11.2%
3 Year9.5%
5 Year12.12%

Profit Growth

1 Year-17.56%
3 Year3.79%
5 Year15.55%

ROE%

1 Year21.69%
3 Year33.79%
5 Year41.11%

ROCE %

1 Year27.48%
3 Year44.79%
5 Year54.04%

Debt/Equity

0.1203

Price to Cash Flow

45.49

Interest Cover Ratio

181.0492

CFO/PAT (5 Yr. Avg.)

1.02442392314637

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 70.86 0.00
Mar 2025 70.86 3.30
Dec 2024 70.86 3.30
Sep 2024 70.86 3.30
Jun 2024 70.86 3.30
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 33.789% over the past 3 years.
  • Company has been maintaining healthy ROCE of 44.7940333333333% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 181.0492.
  • The Company has been maintaining an effective average operating margins of 47.34116% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -112.3898 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.02442392314637.
  • The company has a high promoter holding of 70.86%.

 Limitations

  • The company has shown a poor profit growth of 3.78791942561514% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.50098892871238% for the Past 3 years.
  • The company is trading at a high PE of 92.84.
  • The company is trading at a high EV/EBITDA of 63.073.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 38.83 34.72 39.52 37.74 35.87
Total Expenditure 20.28 19.33 20.65 21.7 21.95
Operating Profit 18.55 15.39 18.87 16.04 13.92
Other Income 0.52 0.32 0.24 1.35 0.27
Interest 0.07 0.08 0.14 0.07 0.04
Depreciation 1.15 1.44 1.56 1.23 2.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 17.86 14.19 17.4 16.09 12.12
Tax 4.62 3.63 4.43 4.09 3.06
Profit After Tax 13.24 10.57 12.97 12 9.06
Adjusted EPS (Rs) 1.21 0.97 1.19 1.1 0.83

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 90.56 114.85 148.39 169.82 150.8
Total Expenditure 50.23 56.81 74.76 91.09 81.96
Operating Profit 40.33 58.05 73.63 78.73 68.84
Other Income 3.27 4.05 6.59 4.37 2.43
Interest 0.98 0.83 0.18 0.23 0.36
Depreciation 1.73 2.23 2.58 3.54 5.37
Exceptional Items 0 0 0 0 0
Profit Before Tax 40.88 59.03 77.46 79.33 65.54
Tax 10.7 15.41 19.5 20.17 16.77
Net Profit 30.18 43.62 57.97 59.16 48.77
Adjusted EPS (Rs.) 2.77 4 5.32 5.43 4.48

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 7.26 7.26 7.26 7.26 10.9
Total Reserves 62.68 96.06 141.88 194.11 237.49
Borrowings 0 0 0 0 29.64
Other N/C liabilities 2.49 2.02 1.9 3.58 2.73
Current liabilities 25.87 31.67 35.7 36.2 37.26
Total Liabilities 98.31 137.02 186.75 241.15 318.01
Assets
Net Block 18.95 19.43 32.66 38.02 41.29
Capital WIP 2.07 12.7 20.59 91.22 184.41
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 2.61 2.77 9.81 9.92 22.26
Other N/C Assets 1.31 9.21 41.53 34.39 1.39
Current Assets 73.37 92.9 82.15 67.6 68.67
Total Assets 98.31 137.02 186.75 241.15 318.01
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 40.88 59.03 77.46 79.33 65.54
Adjustment -0.24 0.15 -2.45 0.46 5.09
Changes in Assets & Liabilities -19.98 -4.36 -15.11 4.19 36.88
Tax Paid -10.13 -14.52 -20.42 -19.78 -16.49
Operating Cash Flow 10.53 40.31 39.48 64.21 91.03
Investing Cash Flow -2.25 -29.83 -20.41 -55.21 -111.82
Financing Cash Flow -5.16 -14 -13.27 -8.59 26.01
Net Cash Flow 3.12 -3.51 5.79 0.41 5.22

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 70.86 70.86 70.86 70.86 70.86
anay rupen choksi 0.02 0.02 0.02 0.02 0.02
dinesh shantilal patel 0.03 0.03 0.03 0.03 0.03
jayshree d patel 0.49 0.49 0.49 0.49 0.49
nysha rupen choksi 0.02 0.02 0.02 0.02 0.02
pharmaceutical business g... - 47.02 47.02 47.02 47.02
reena s patel 0.04 0.04 - 0.04 0.04
sachin dinesh patel 0.05 0.05 - 0.05 0.05
themis medicare limited - 23.19 23.19 23.19 23.19
reena s patel - - 0.04 - -
sachin dinesh patel - - 0.05 - -
themis medicare limited 23.19 - - - -
pharmaceutical business g... 47.02 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 29.14 29.14 29.14 29.14 29.14
llp 0.47 0.45 0.45 0.62 0.60
quant mutual fund - quant... 1.15 1.15 1.15 1.15 1.15
dipak kanayalal shah 1.02 1.02 1.02 1.02 -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit SMERA
Credit SMERA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q2FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q3FY24
Presentation Q3FY22
Presentation Q2FY22
Presentation Q1FY25
Presentation Q1FY21
Presentation H1FY24

Company News

Guj. Themis Biosyn Stock Price Analysis and Quick Research Report. Is Guj. Themis Biosyn an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Guj. Themis Biosyn. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Guj. Themis Biosyn has a PE ratio of 92.8437049524787 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Guj. Themis Biosyn has ROA of 17.4447% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Guj. Themis Biosyn has a Current ratio of 1.8432.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Guj. Themis Biosyn has a ROE of 21.688%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Guj. Themis Biosyn has a Debt to Equity ratio of 0.1203 which means that the company has low proportion of debt in its capital.

  • Sales growth: Guj. Themis Biosyn has reported revenue growth of -11.2011% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Guj. Themis Biosyn for the current financial year is 45.6528154196389%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Guj. Themis Biosyn is Rs 0.67 and the yield is 0.1758%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Guj. Themis Biosyn is Rs 4.0929. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Guj. Themis Biosyn in Ticker for free. Also, one can get the intrinsic value of Guj. Themis Biosyn by using Valuation Calculators, which are available with a Finology ONE subscription. 

Guj. Themis Biosyn FAQs

Q1. What is Guj. Themis Biosyn share price today?
Ans: The current share price of Guj. Themis Biosyn is Rs 380.

Q2. What is the market capitalisation of Guj. Themis Biosyn?
Ans: Guj. Themis Biosyn has a market capitalisation of Rs 4140.68007 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Guj. Themis Biosyn?
Ans: The PE ratio of Guj. Themis Biosyn is 92.8437049524787 and the P/B ratio of Guj. Themis Biosyn is 16.083839127748, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Guj. Themis Biosyn share?
Ans: The 52-week high share price of Guj. Themis Biosyn is Rs 410.7, and the 52-week low share price of Guj. Themis Biosyn is Rs 208.

Q5. Does Guj. Themis Biosyn pay dividends?
Ans: Currently, Guj. Themis Biosyn pays dividends. Dividend yield of Guj. Themis Biosyn is around 0.1758%.

Q6. What are the face value and book value of Guj. Themis Biosyn shares?
Ans: The face value of Guj. Themis Biosyn shares is Rs 1, while the book value per share of Guj. Themis Biosyn is around Rs 23.6262. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Guj. Themis Biosyn?
Ans: Guj. Themis Biosyn has a total debt of Rs 29.8899 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Guj. Themis Biosyn?
Ans: The ROE of Guj. Themis Biosyn is 21.688% and ROCE of Guj. Themis Biosyn is 27.4793%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Guj. Themis Biosyn a good buy for the long term?
Ans: The Guj. Themis Biosyn long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Guj. Themis Biosyn undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Guj. Themis Biosyn appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Guj. Themis Biosyn’s financials?
Ans: You can review Guj. Themis Biosyn’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Guj. Themis Biosyn
X